Aptuit LLC, a pharmaceutical services company headquartered in Greenwich, has announced it has acquired the Swiss biotech firm Exquiron Biotech AG for an undisclosed amount.
Aptuit provides early discovery to mid-phase drug development services in the pharmaceutical industry including drug design and discovery among other specialties.
According to the company, Exquiron, a specialist in contract research organization dedicated to early phase drug discovery solutions, was acquired to meet customer demand for fully integrated outsourced discovery services.
“Aptuit specializes in the discovery of small molecules across a wide range of therapeutic areas including neuroscience, oncology, infectious disease, inflammation, respiratory and others,” said Jonathan Goldman, Aptuit CEO. “The acquisition of Exquiron broadens our scientific excellence in advanced integrated discovery by incorporating capabilities in early discovery.”
Founded in 2013, Exquiron will expand Aptuit”™s international presence by adding facilities in Switzerland to those already in the United Kingdom and Italy.
